81 related articles for article (PubMed ID: 34478210)
21. Vismodegib Experience in a Renal Transplant Patient With Basal Cell Carcinoma.
Rahatli S; Oguz A; Altundag O; Haberal M
Exp Clin Transplant; 2020 Jun; ():. PubMed ID: 32490762
[TBL] [Abstract][Full Text] [Related]
22. Advanced Basal Cell Carcinoma: Epidemiology and Therapeutic Innovations.
Mohan SV; Chang AL
Curr Dermatol Rep; 2014; 3(1):40-45. PubMed ID: 24587976
[TBL] [Abstract][Full Text] [Related]
23. Real World Data on Efficacy and Safety of Vismodegib in Greek Patients with Advanced, Multiple and Metastatic Basal Cell Carcinoma.
Sgouros D; Pappa G; Syrmali A; Theodoropoulos K; Theotokoglou S; Bozi E; Damaskou V; Panayiotides IG; Katoulis AC
Indian J Dermatol; 2022; 67(6):796-797. PubMed ID: 36998872
[No Abstract] [Full Text] [Related]
24. A Multidisciplinary approach to metastatic giant basal cell carcinoma-A case report.
Lehto LET; Ristola MT; Mäntylä V; Pajula S
JPRAS Open; 2024 Jun; 40():190-193. PubMed ID: 38577347
[TBL] [Abstract][Full Text] [Related]
25. Vismodegib (erivedge) for advanced Basal cell carcinoma.
Fellner C
P T; 2012 Dec; 37(12):670-82. PubMed ID: 23319845
[TBL] [Abstract][Full Text] [Related]
26. Metastatic basal cell carcinoma to the lungs: Case report and review of literature.
Nongrum HB; Bhuyan D; Royte V; Dkhar H
Indian Dermatol Online J; 2014 Nov; 5(Suppl 1):S26-9. PubMed ID: 25506559
[TBL] [Abstract][Full Text] [Related]
27. Same-site transdifferentiation of basal cell carcinoma to squamous cell carcinoma as a mechanism of vismodegib treatment resistance: Two cases requiring multimodal and multidisciplinary limb-sparing techniques.
Burgess BA; Wang RJ; Owen JL
JAAD Case Rep; 2024 Feb; 44():17-19. PubMed ID: 38292569
[No Abstract] [Full Text] [Related]
28. Recovery of Facial Nerve Function After Vismodegib Treatment of Advanced Basal Cell Carcinoma.
Jansen C; Bailey AM; Hsia LB
Dermatol Surg; 2024 May; ():. PubMed ID: 38771950
[No Abstract] [Full Text] [Related]
29. Clinical presentation and treatment of advanced basal-like lung carcinoma.
Xie J; Zhang M; Wang H; Guo X; Han T; Tong W; Liu H; Zhang L
Panminerva Med; 2024 Feb; ():. PubMed ID: 38407012
[No Abstract] [Full Text] [Related]
30. Vismodegib for treatment of periocular basal cell carcinoma - 6-year experience from a tertiary cancer center.
Xavier C; Lopes E; Bexiga C; Moura C; Gouveia E; Duarte AF
An Bras Dermatol; 2021; 96(6):712-716. PubMed ID: 34518037
[TBL] [Abstract][Full Text] [Related]
31. Real-World Experience of Vismodegib in Advanced Basal Cell Carcinoma at a Canadian Cancer Center.
Tong J; Mitchell B; Roth K; Logan D; Ernst S
J Cutan Med Surg; 2022; 26(2):143-148. PubMed ID: 34663118
[TBL] [Abstract][Full Text] [Related]
32. Key Clinical Adverse Events in Patients with Advanced Basal Cell Carcinoma Treated with Sonidegib or Vismodegib: A Post Hoc Analysis.
Gutzmer R; Loquai C; Robert C; Dréno B; Guminski A; Lewis K; Arntz R; Martelli S; Squittieri N; Kheterpal M
Dermatol Ther (Heidelb); 2021 Oct; 11(5):1839-1849. PubMed ID: 34490549
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of Watchful Waiting and Tumor Behavior in Patients With Basal Cell Carcinoma: An Observational Cohort Study of 280 Basal Cell Carcinomas in 89 Patients.
van Winden MEC; Hetterschijt CRM; Bronkhorst EM; van de Kerkhof PCM; de Jong EMGJ; Lubeek SFK
JAMA Dermatol; 2021 Oct; 157(10):1174-1181. PubMed ID: 34495284
[TBL] [Abstract][Full Text] [Related]
34. Vismodegib treatment in advanced basal cell carcinomas: Real-life experience.
Villani A; Fabbrocini G; Costa C; Scalvenzi M
Dermatol Ther; 2022 Jan; 35(1):e15195. PubMed ID: 34751490
[No Abstract] [Full Text] [Related]
35. Efficacy and tolerability of vismodegib treatment in locally advanced and metastatic basal cell carcinoma: Retrospective real-life data.
Gürbüz M; Doğan İ; Akkuş E; Ermiş H; Utkan G; Vatansever S; Taş F
Dermatol Ther; 2021 Nov; 34(6):e15122. PubMed ID: 34478210
[TBL] [Abstract][Full Text] [Related]
36. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
Sekulic A; Migden MR; Basset-Seguin N; Garbe C; Gesierich A; Lao CD; Miller C; Mortier L; Murrell DF; Hamid O; Quevedo JF; Hou J; McKenna E; Dimier N; Williams S; Schadendorf D; Hauschild A;
BMC Cancer; 2017 May; 17(1):332. PubMed ID: 28511673
[TBL] [Abstract][Full Text] [Related]
37. Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies.
Jacobsen AA; Aldahan AS; Hughes OB; Shah VV; Strasswimmer J
JAMA Dermatol; 2016 Jul; 152(7):816-24. PubMed ID: 27096888
[TBL] [Abstract][Full Text] [Related]
38. Vismodegib: A Review in Advanced Basal Cell Carcinoma.
Frampton JE; Basset-Séguin N
Drugs; 2018 Jul; 78(11):1145-1156. PubMed ID: 30030732
[TBL] [Abstract][Full Text] [Related]
39. Vismodegib in Locally Advanced Basal Cell Carcinoma in Slovenia.
Mesti T; Sever M; Ocvirk J
Dermatology; 2023; 239(1):158-164. PubMed ID: 35896082
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
